Vimarsana
Biggest News Aggregation in the World

Lisa Ellen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lisa Ellen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lisa Ellen Today - Breaking & Trending Today

RICHARD L. MEDCALF | News, Sports, Jobs - The Herald Star - Vimarsana News

RICHARD L. MEDCALF | News, Sports, Jobs - The Herald Star

Richard L. “Rich” Medcalf, 55, of Steubenville, Ohio passed away on Friday, January 26, 2024 at Trinity West ER. He was born on October 13, 1968 in St

The 2023 Jim Ridley Film Poll - Vimarsana News

The 2023 Jim Ridley Film Poll

Dedicated to the Scene’s late longtime editor and critic, our poll asks cinephiles, critics and industry insiders about 2023 in film. This year's winners include 'Past Lives,' 'Poor Things,' 'The Holdovers' and more.

The 2022 Jim Ridley Film Poll - Vimarsana News

The 2022 Jim Ridley Film Poll

Dedicated to the Scene’s late longtime editor and critic, our poll asks cinephiles, critics and industry insiders about 2022 in film

Ferring Pharmaceuticals: Ferring Receives U.S. FDA Approval for REBYOTA (fecal microbiota, live-jslm) - A Novel First-in-Class Microbiota-Based Live Biotherapeutic - Vimarsana News

Ferring Pharmaceuticals: Ferring Receives U.S. FDA Approval for REBYOTA (fecal microbiota, live-jslm) - A Novel First-in-Class Microbiota-Based Live Biotherapeutic

Ferring's novel first-in-class REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment

Ferring Pharmaceuticals: Ferring Presents New Subgroup Analyses of Health-Related Quality of Life and Safety and Efficacy Data at IDWeek 2022 for RBX2660, Its Investigational Microbiota-based Live Biotherapeutic - Vimarsana News

Ferring Pharmaceuticals: Ferring Presents New Subgroup Analyses of Health-Related Quality of Life and Safety and Efficacy Data at IDWeek 2022 for RBX2660, Its Investigational Microbiota-based Live Biotherapeutic

Subgroup analysis of Phase 3 trial (PUNCH CD3) looked at health-related quality of life data in patients treated with RBX2660 versus placebo Separate subgroup analysis reviewed efficacy and